View Older Stories View More Recent Stories

Jun 23, 2018 08:00AM Investigational Doses of Lilly's Once-Weekly Trulicity® (dulaglutide) Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes
Jun 12, 2018 06:15AM Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer's Disease Due to Futility
Jun 12, 2018 02:00AM Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Jun 1, 2018 12:14PM Eli Lilly & Co. (LLY), Incyte (INCY) Confirm FDA Approval of 2-mg OLUMIANT
Jun 1, 2018 12:04PM FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
May 23, 2018 10:02AM Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families
Apr 24, 2018 06:01AM Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
Apr 23, 2018 08:11PM FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
Apr 16, 2018 08:06AM Eli Lilly & Co. (LLY) & Boehringer Ingelheim Announces Academic Collaboration with Oxford University for Jardiance Research
Apr 16, 2018 08:00AM Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
Apr 4, 2018 07:02AM Eli Lilly & Co. (LLY), Sigilon Therapeutics Announce Pact to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Apr 4, 2018 07:00AM Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Mar 8, 2018 06:30AM EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research
Mar 6, 2018 08:05AM Lilly (LLY), Boehringer Ingelheim Expand Heart Failure Program for Jardiance
Mar 6, 2018 08:00AM Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
Feb 26, 2018 06:51AM Lilly (LLY) Says Data Show Trulicity Combo Improves Blood Sugar Control in People with Type 2 Diabetes
Feb 26, 2018 06:45AM New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Feb 14, 2018 01:17PM Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jan 8, 2018 09:03AM Eli Lilly & Co. (LLY) Announces Collaboration with Livongo on Real-World Diabetes Research
Jan 8, 2018 09:00AM Livongo and Lilly Collaborate on Real-World Diabetes Research
Dec 14, 2017 12:30PM Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin
Dec 6, 2017 09:01AM Juno Therapeutics (JUNO) Reports Licensing Agreements with Lilly (LLY), OncoTracker, and Fred Hutchinson Cancer Research Center
Dec 5, 2017 09:03AM Eli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery System
Dec 5, 2017 09:00AM Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System
Nov 13, 2017 06:45PM Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
Nov 13, 2017 10:10AM Trump taps ex-pharma executive Azar as U.S. health secretary
Nov 5, 2017 09:00AM ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo
Oct 30, 2017 09:00AM Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting
Oct 4, 2017 09:00AM Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes
Oct 3, 2017 02:30PM Life Sciences Companies Adopt Veeva Vault Development Cloud as Their Technology Foundation for Drug Development
Sep 25, 2017 08:30AM Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, includi
Sep 14, 2017 09:02AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Announces Baricitinib Meets Primary Endpoint in Phase 2 Study
Sep 14, 2017 09:00AM Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
Sep 12, 2017 07:10AM Eli Lilly & Co. (LLY) Reports New Analyses of EMPA-REG OUTCOME Trial Showed that Jardiance (Empagliflozin) Tablets Reduced the Risk of Cardiovascular Death
Sep 12, 2017 06:59AM Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
Sep 11, 2017 09:03AM Eli Lilly & Co. (LLY) to Present New Data for Olumiant and Taltz at EADV
Sep 11, 2017 09:00AM Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
Aug 30, 2017 06:46AM Eli Lilly (LLY) Plans to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Aug 30, 2017 06:45AM Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
Jul 31, 2017 09:00AM Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular de
Jul 25, 2017 06:18AM Lilly (LLY), Incyte (INCY) Announce Resubmission of NDA for Baricitinib Will Be Delayed Beyond 2017
Jul 25, 2017 06:15AM Lilly and Incyte Provide Update on Baricitinib
Jul 10, 2017 08:00AM Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment
Jul 3, 2017 08:00AM Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis
Jun 28, 2017 09:12AM Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications
Jun 27, 2017 08:00AM Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
Jun 16, 2017 06:18AM Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Present New Safety & Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis
Jun 16, 2017 04:15AM New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Jun 13, 2017 06:01PM Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)
View More Recent Stories View Older Stories